These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 19738020)

  • 41. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
    Blondeau JM; Blondeau LD; Hesje C; Borsos S
    J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
    Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
    Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats.
    Boothe DM; Boeckh A; Simpson RB; Dubose K
    J Vet Intern Med; 2006; 20(6):1297-306. PubMed ID: 17186841
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Jan; 50(1):243-9. PubMed ID: 16377693
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.
    Firsov AA; Golikova MV; Strukova EN; Portnoy YA; Romanov AV; Edelstein MV; Zinner SH
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1014-9. PubMed ID: 25451050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.
    Vasseur MV; Laurentie M; Rolland JG; Perrin-Guyomard A; Henri J; Ferran AA; Toutain PL; Bousquet-Mélou A
    Antimicrob Agents Chemother; 2014; 58(3):1744-8. PubMed ID: 24395228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.
    Strukova EN; Portnoy YA; Zinner SH; Firsov AA
    J Antimicrob Chemother; 2016 Mar; 71(3):678-84. PubMed ID: 26626718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection.
    Bakker-Woudenberg IA; ten Kate MT; Goessens WH; Mouton JW
    Antimicrob Agents Chemother; 2006 Sep; 50(9):2919-25. PubMed ID: 16940082
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: report from the Antimicrobial Resistance Rate Epidemiology Study Team.
    Jones RN; Rubino CM; Bhavnani SM; Ambrose PG;
    Antimicrob Agents Chemother; 2003 Jan; 47(1):292-6. PubMed ID: 12499204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the
    Krajewska J; Tyski S; Laudy AE
    Antimicrob Agents Chemother; 2023 May; 67(5):e0137322. PubMed ID: 37022162
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PK-PD integration and modeling of marbofloxacin in sheep.
    Sidhu PK; Landoni MF; Aliabadi FS; Lees P
    Res Vet Sci; 2010 Feb; 88(1):134-41. PubMed ID: 19523661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A unified anti-mutant dosing strategy.
    Zhao X; Drlica K
    J Antimicrob Chemother; 2008 Sep; 62(3):434-6. PubMed ID: 18544596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
    Allen GP; Bierman BC
    Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of bacterial load on pharmacodynamics and susceptibility breakpoints for tigecycline and Klebsiella pneumoniae.
    Tsala M; Vourli S; Daikos GL; Tsakris A; Zerva L; Mouton JW; Meletiadis J
    J Antimicrob Chemother; 2017 Jan; 72(1):172-180. PubMed ID: 27650184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.